About: Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)
Creator	Pagano, F Alimonti, & Alimonti, A Alimonti, Andrea Carbone, G Catapano, C Cavalli, A Montopoli, M Prayer-Galetti, T Ragazzi, E Rugge, M Vettor, R Zorzi, M Zumerle, S
topic	covid:984ca7e3c9a03d6dc63933889f407606f265ac2d#this
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Cell entry of SARS-CoV-2 depends on binding of the viral spike (S) proteins to ACE2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is upregulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. MATERIALS AND METHODS: We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the COVID-19 pandemic. The parameters used for each COVID-19 positive patient were gender, hospitalization, admission to intensive care unit (ICU), death, tumor diagnosis, prostate cancer diagnosis, and androgen-deprivation therapy (ADT). RESULTS: There were 9280 SARS-CoV-2 positive patients in the Veneto on April 1, 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 Million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2 positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared to patients who did not receive ADT (OR 4.05; 95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT to patients with any other type of cancer (OR 5.17; 95% CI 2.02-13.40). CONCLUSION: Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections than non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1016/j.annonc.2020.04.479
bibo:pmid	32387456
has license	no-cc
sha1sum (hex)	984ca7e3c9a03d6dc63933889f407606f265ac2d
schema:url	https://doi.org/10.1016/j.annonc.2020.04.479
resource representing a document's title	Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)
has PubMed Central identifier	PMC7202813
has PubMed identifier	32387456
schema:publication	Ann Oncol
resource representing a document's body	covid:984ca7e3c9a03d6dc63933889f407606f265ac2d#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/984ca7e3c9a03d6dc63933889f407606f265ac2d
is schema:about of	named entity 'prostate cancer' named entity 'infections' named entity 'PROTEIN ' named entity 'HYPOTHESIS' named entity 'WORK' named entity 'ACE2' named entity 'Cell' named entity 'SARS-CoV-2' named entity 'infections' named entity 'levels' named entity 'TMPRSS2' named entity 'patients' named entity 'TMPRSS2' named entity '+41 91' named entity 'SARS-CoV-2' named entity 'prostate cancer' named entity 'prostate cancer' named entity 'SARS' named entity 'ACE2' named entity 'tumor' named entity 'SARS-CoV-2' named entity 'severe infections' named entity 'Statistical significance' named entity 'transcription' named entity 'lung' named entity 'ICU' named entity 'SARS-CoV-2' named entity 'upregulated' named entity 'androgens' named entity 'nuclear receptors' named entity 'MERS-CoV' named entity 'SARS-CoV-2' named entity 'human lung' named entity 'antibody response' named entity 'Veneto' named entity 'neutrophils' named entity 'Veneto' named entity 'SARS' named entity 'Veneto' named entity 'TGFβ' named entity 'GRE' named entity 'atypical pneumonia' named entity 'SARS-CoV-2' named entity 'androgen' named entity 'lung' named entity 'viruses' named entity 'mortality rate' named entity 'SARS-CoV-2' named entity 'ICU' named entity 'androgen receptor' named entity 'androgen' named entity 'SARS-CoV-2' named entity 'prostate' named entity 'gene' named entity 'Androgen' named entity 'influenza' named entity 'SARS-CoV-2' named entity 'TMPRSS2' named entity 'April 1, 2020' named entity 'chi-square test' named entity 'infection' named entity 'androgen-dependent' named entity 'camostat' named entity 'infection' named entity 'TMPRSS2' named entity 'TMPRSS2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software